Target intelligence / Profile preview

SH2 domain-containing protein 4A (SH2D4A)

Target
SH2D4A
Molecular classification
Adapter protein, SH2 domain-containing protein, Signal transduction molecule, Type I SH2 domain family
01

Overview

SH2D4A is a ubiquitously expressed adapter protein defined by a single C-terminal SH2 (Src homology 2) domain highly homologous to signaling proteins TSAd and ALX. It is primarily cytoplasmic and involved in mediating protein-protein interactions important for signal transduction, especially in immune cells (T cells, B cells, macrophages, dendritic cells). SH2D4A modulates estrogen receptor (ESR1) signaling by inhibiting estrogen-induced cell proliferation, and acts as a tumor suppressor by interacting with the transcription factor STAT3 and mitochondrial prohibitins; loss of SH2D4A contributes to increased mitochondrial respiration and cancer progression. Despite structural similarity to key adapter proteins regulating TCR signaling, SH2D4A is dispensable for T cell development and function under normal conditions in both mice and humans. Chromosomal loss or deletion (chromosome 8p) is associated with several cancers, implicating SH2D4A as a potential tumor suppressor and therapeutic target.

Other names
SH2 domain-containing protein 4ASH2D4APPP1R38SH2AFLJ20967Protein SH(2)AProtein phosphatase 1 regulatory subunit 38
02

Mechanism of action

FL3: disrupts the interaction of SH2D4A with prohibitin and STAT3, modulates mitochondrial STAT3 signaling, counteracts increased mitochondrial respiration caused by SH2D4A loss SH2D4A blocks PLCG binding to ESR1 (estrogen receptor), repressing estrogen-induced transcriptional response

03

Biological functions

Signal transductionRegulation of T cell activationInhibition of estrogen receptor (ESR1) signalingInhibition of cell proliferation (esp. estrogen-induced)Cytoplasmic signaling adaptorRegulation of mitochondrial function and interaction with STAT3 and prohibitin
04

Disease associations

Cancer (chromosome 8p deletion, tumor suppression, altered mitochondrial signaling)Potential tumor suppressor (loss/deletion implicated in cancer)
05

Safety considerations

No major safety concerns documented specifically for SH2D4A targetingGeneral risks may relate to disruption of T cell signaling and mitochondrial function
06

Interacting drugs

FL3 (a prohibitin ligand, modifies PHB/STAT3/SH2D4A interactions)

1 more in the full profile.

07

Biomarkers

Deletion/low expression of SH2D4A (chromosome 8p loss) is a marker of poor cancer prognosisMay serve as a biomarker for STAT3 pathway modulation in cancers

Beyond the preview

Go deeper on SH2 domain-containing protein 4A (SH2D4A).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on SH2 domain-containing protein 4A (SH2D4A).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call